Curis Q3 net loss $13.3M, cuts ~30% of workforce to focus on emavusertib, cash runway into 2025

CURIS INC

2022-Q3 EPS reported -$0.49 revenue$7,275,000

Net loss of $13.3M ($0.14/shr) vs $11.1M ($0.12/shr) in Q3 2021; revenues $2.8M.
Plan to reduce workforce by ~30% and reallocate resources to emavusertib pipeline.
Cash & equivalents $98.7M as of Sep 30; expects cash runway into 2025.
Updated TakeAim Leukemia data for emavusertib to be presented at ASH 2022 (Dec 10-13).
FDA has allowed enrollment to resume in TakeAim Lymphoma and monotherapy dose finding of TakeAim Leukemia.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CURIS INC reported third quarter ended September 30, 2022 results: revenue $2.8 million, net income net loss of $13.3 million, EPS $0.14 per share on both a basic and diluted basis.

Period: third quarter ended September 30, 2022
Revenue: $2.8 million
Net income: net loss of $13.3 million
EPS: $0.14 per share on both a basic and diluted basis
Result: reported results

Exact text from the filing

to a net loss of $31.8 million, or $0.35 per share on both a basic and diluted basis for the same period in 2021. Revenues, net for the third quarter of 2022 and 2021 were $2.8 million and $3.0 million, respectively. Revenues, net for the nine months ended September 30, 2022 were $7.3 million as compared to $7.5 million for the same period in 2021. Revenues for

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-22-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.